Results of a pharmacoeconomic analysis of the rationality of the use of acute myeloid leukemia chemotherapy regimens with the use of various doses of cytarabine
A pharmacoeconomic study of the rationality of the use of various chemotherapy regimens (“7 + 3” scheme) in the treatment of patients with acute forms of myeloid leukemia has been carried out. The use of the chemotherapy regimen “7 + 3” with 200 mg / m2 / per day dosage of cytarabine on 1-7 days all...
Main Authors: | Panfilova Hanna, Goncharova Anastasiya, Korzh Iuliia, Zhirova Irina, Tsurikova Oksana, Bezuglaia Natalia |
---|---|
Format: | Article |
Language: | English |
Published: |
EDP Sciences
2021-01-01
|
Series: | BIO Web of Conferences |
Online Access: | https://www.bio-conferences.org/articles/bioconf/full_html/2021/02/bioconf_ils2021_03003/bioconf_ils2021_03003.html |
Similar Items
-
Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia
by: Baohang Zhang, et al.
Published: (2023-05-01) -
Combination of cyclophosphamide and cytarabine as induction regimen for newly diagnosed adult acute myeloid leukemia
by: Qingguo Liu, et al.
Published: (2020-07-01) -
Role of Intracellular Drug Disposition in the Response of Acute Myeloid Leukemia to Cytarabine and Idarubicin Induction Chemotherapy
by: Gabriela Rodríguez-Macías, et al.
Published: (2023-06-01) -
Effect of Chemotherapy Cytarabine and Acute Myeloid Leukemia on the Development of Spermatogenesis at the Adult Age of Immature Treated Mice
by: Bara’ah Khaleel, et al.
Published: (2022-04-01) -
Influence of UGT1A1 polymorphisms on the outcome of acute myeloid leukemia patients treated with cytarabine-base regimens
by: Peng Chen, et al.
Published: (2018-07-01)